Prasad Kulkarni joins Callam Davidson of The Lancet to discuss the safety and immunogenicity of a bivalent conjugate vaccine against typhoid and paratyphoid, following the publication of a phase 1 trial.

Read the full article:
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)00249-6/fulltext?dgcid=buzzsprout_icw_podcast_generic_lancet

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv